Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,476
datasets available to search
ShareScore release 0.9.0
Dataset results
3,476 results for “Parkinson disease”
Transcriptomic changes in oligodendrocytes and precursor cells predicts clinical outcomes of Parkinson's disease
GEO Series GSE272760. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Nigrostriatal Tau Pathology in parkinsonism and Parkinson's disease
Open the record for dataset details and reuse information.
Unravelling cell type-specific responses to Parkinson's Disease at single cell resolution
<p>Data set including raw and pre-processed files of spatial transcriptomics associated with the study mentioned above.</p>
Polymorphisms of cytochromes P450 and glutathione S-transferases synergistically modulate risk for Parkinson's disease
<p><span><strong>Background</strong>: </span><span>Environmental substances such as p</span><span>esticides </span><span>are well-known in </span><span>link </span><span>with</span><span> PD </span><span>risk</span><span>.</span><span> E</span><span>nzymes </span><span>including </span><span>cytochromes P450 (CYPs)</span><span>,</span><span> esterases </span><span>and </span><span>glutathione S-transferases (GSTs) </span><span>are responsible for the x</span><span>enobiotic </span><span>metabolism and </span><span>may functionally compensate each other </span><span>for subtypes in the same class. W</span><span>e hypothesize that the genetic effects </span><span>of each class </span><span>modulate PD risk stronger in a synergistic way</span> <span>than individually.</span></p> <p><span><strong>Methods</strong>: </span><span>We selected 14 polymorphic loci out of 13 </span><span>enzymes in the classes of</span><span> CYP, esterase, and GST, and recruited a cohort of 1026 PD and control subjects from eastern China. The genotypes were identified using improved multiplex ligation detection reaction, and analyzed using multiple models.</span></p> <p><span><strong>Results</strong>:</span><span> A total of 13 polymorphisms remained after Hardy-Weinberg equilibrium analysis. None of the polymorphisms were independently associated with PD risk after Bonferroni correction either by logistic regression or genetic models. In contrast, interaction analyses detected increased resistance to PD risk in individuals carrying the rs12441817/CC (<em>CYP1A1</em>) and rs2070676/G (<em>CYP2E1</em>) genotypes (P = 0.002, OR = </span><span>0.393</span><span>, 95% CI = </span><span>0.216-0.715)</span><span>,</span><span> or carrying the <em>GSTM1</em>-present, <em>GSTT1</em>-null, rs156697/G (<em>GSTO2</em>) and rs1695/AA (<em>GSTP1</em>) genotypes (<em>P</em> = 0.003, OR = </span><span>0.348</span><span>, 95% CI = </span><span>0.171-0.706</span><span>), but not with genotypes of esterases.</span></p> <p><span><strong>Conclusions</strong>:</span><span> We demonstrate a presence of synergistic but not individual impact on PD susceptibility in polymorphisms of <em>CYPs</em> and <em>GSTs</em>. The results indicate that the genetic interplay leads the way to PD development for xenobiotic metabolizing enzymes.</span></p>
Data from: Sensory-Behavioral Deficits in Parkinson's Disease: Insights from a 6-OHDA Mouse Model
<table> <tbody> <tr> <td>Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the striatum, predominantly associated with motor symptoms. However, non-motor deficits, particularly sensory symptoms, often precede motor manifestations, offering a potential early diagnostic window. The impact of non-motor deficits on sensation behavior and the underlying mechanisms remains poorly understood. In this study, we examined changes in tactile sensation within a Parkinsonian state by employing a mouse model of PD induced by 6-hydroxydopamine (6-OHDA) to deplete striatal dopamine (DA). Leveraging the conserved mouse whisker system as a model for tactile-sensory stimulation, we conducted psychophysical experiments to assess sensory-driven behavioral performance during a tactile detection task in both the healthy and Parkinson-like states. Our findings reveal that DA depletion induces pronounced alterations in tactile sensation behavior, extending beyond expected motor impairments. We observed diverse behavioral deficits, spanning detection performance, task engagement, and reward accumulation, among lesioned individuals. While subjects with extreme DA depletion consistently showed severe sensory behavioral deficits, others with substantial DA depletion displayed minimal changes in sensory behavior performance. Moreover, some exhibited moderate degradation of behavioral performance, likely stemming from sensory signaling loss rather than motor impairment. The implementation of a sensory detection task is a promising approach to quantify the extent of impairments associated with DA depletion in the animal model. This facilitates the exploration of early non-motor deficits in PD, emphasizing the importance of incorporating sensory assessments in understanding the diverse spectrum of PD symptoms.</td> </tr> </tbody> </table>
Membrane remodeling properties of the Parkinson's disease protein LRRK2
<p>This data set contains the primary data associated with the publication in PNAS</p>
Impact of Myofascial Release on Dysphagia in Parkinson's Disease Patients
ClinicalTrials.gov study NCT06328296. IPD Sharing: Not stated. Countries: 0. Publications: 0.
How Traditional Chinese Medicine Exercise Improves Parkinson Disease
ClinicalTrials.gov study NCT06303908. IPD Sharing: NO. Countries: 0. Publications: 0.
Consensus Statements on Deep Brain Stimulation in Patients With Parkinson's Disease
ClinicalTrials.gov study NCT07173660. IPD Sharing: NO. Countries: 0. Publications: 0.
Autocorrelated Rhythmic Auditory Stimulations for Parkinson's Disease Patients
ClinicalTrials.gov study NCT03716674. IPD Sharing: NO. Countries: 0. Publications: 0.
Neuromodulation on Motor Function in Parkinson's Disease
ClinicalTrials.gov study NCT02250690. IPD Sharing: Not stated. Countries: 0. Publications: 0.
TRANSEURO Open Label Transplant Study in Parkinson's Disease
ClinicalTrials.gov study NCT01898390. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Deep Brain Stimulation for Parkinson's Disease: the Globus Pallidus Internus Versus Subthalamic Nucleus
ClinicalTrials.gov study NCT02647372. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
ClinicalTrials.gov study NCT07280299. IPD Sharing: NO. Countries: 0. Publications: 0.
Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease
ClinicalTrials.gov study NCT00115427. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Relaxation Guided Imagery for Treatment of Pain in Parkinson's Disease
ClinicalTrials.gov study NCT01865097. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease
ClinicalTrials.gov study NCT02231905. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Validation of HaGuide Software Module Accuracy in Mapping STN Boundaries in Parkinson's Disease Patients Who Underwent DBS Procedure
ClinicalTrials.gov study NCT03363724. IPD Sharing: NO. Countries: 0. Publications: 0.
Clinical Trial of Vildagliptin in Early Parkinson's Disease
ClinicalTrials.gov study NCT06951334. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Improving Quality of Life in Early Parkinson's Disease
ClinicalTrials.gov study NCT04590612. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.